Consolidative therapy with stem cell transplantation improves survival of聽patients with mantle cell lymphoma after any induction regimen
- 作者：Nishitha Reddy ; nishitha.reddy@vanderbilt.edu ; John P. Greer ; Stacey Goodman ; Adetola Kassim ; David S. Morgan ; Wichai Chinratanalab ; Stephen Brandt ; Brian Englehardt ; Olalekan Oluwole ; Madan H. Jagasia ; Bipin N. Savani
- 刊名：Experimental Hematology
- 出版年：2012
- 期刊代码：100_0301472x
- 类别：med
- 出版时间：May, 2012
- 卷：40
- 期：5
- 页码：359-366
- 文件大小：267 K
摘要
Intensive induction regimen followed by high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) is frequently used to improve outcomes in patients with mantle-cell lymphoma. The comparative impact of conventional vs intensive induction regimen before transplantation is unknown. Forty-eight patients with mantle-cell lymphoma receiving SCT at our institution between January 2000 and December 2010 were included in this study. At the time of initial presentation, 43 (89.5%) had stage IV disease and 18 (37.5%) received more than one chemotherapy regimen before transplantation. Forty patients underwent auto-SCT and 7 had allogeneic SCT (allo-SCT); 1 patient had an allo-SCT for relapsed disease after auto-SCT. At the time of this analysis (median follow-up of 6 years from diagnosis and 4 years from transplantation), 40 patients (88%) were alive with a 5-year disease-free survival of 74.8%. Age, disease stage, number of regimens pre-SCT, pre-SCT disease status, and type of SCT had no impact on long-term outcomes. Importantly, there were no differences among the types of induction regimen on outcomes in this cohort receiving SCT. Based on our data, we believe that future studies should focus on strategies to prevent disease relapse rather than comparing induction regimens before stem cell transplantation.